Additionally, in renal cell carcinoma, we also showed that the existence of CTCs with expression of PD-L1 before PD-1 blockade therapy could be a predictive factor for disease prognosis and that the dynamic changes in CTC counts may be used to monitor treatment response. This evidence concerns the gene CD274 and renal cell carcinoma.